Results 221 to 230 of about 51,089 (251)
Some of the next articles are maybe not open access.
Heart of the matter: A GP’s guide to cardiac myosin inhibitors
InnovAiT: Education and inspiration for general practiceHypertrophic obstructive cardiomyopathy (HOCM) is a heritable heart condition. It causes hypertrophy of the heart muscle and left ventricular outflow tract obstruction. Hypertrophic cardiomyopathy (HCM) is one of the most prevalent inherited cardiac disorders, with more than 1400 mutations discovered.
Tamara Naneishvili +8 more
openaire +1 more source
Cardiac Myosin Inhibitors: Unlocking Potential to Improve Treatment in Hypertrophic Cardiomyopathy
Circulation, 2023Aslan Teyfik Turer, Andrew Wang
openaire +2 more sources
Cardiac Myosin Inhibitors for Obstructive Hypertrophic Cardiomyopathy
Journal of the American College of Cardiology, 2022openaire +1 more source
Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery, 2023
Michael J, Litt, Sharlene M, Day
openaire +2 more sources
Michael J, Litt, Sharlene M, Day
openaire +2 more sources
Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure
New England Journal of Medicine, 2021John R Teerlink +2 more
exaly
Cardiac myosin inhibitors in the treatment of hypertrophic cardiomyopathy (literature review)
Pharmateca, 2023L.V. Kononenko Kononenko +2 more
openaire +1 more source